OR WAIT 15 SECS
October 22, 2015.
The treatment market for multiple myeloma across the Asia-Pacific (APAC) countries of China, India, Japan, and Australia will rise in value from $1.7 billion in 2014 to $2.8 billion by 2021, a CAGR of 7.4%, according to GBI Research.
The company’s new report states that growth will primarily be driven by the emergence of novel therapeutics that have significantly improved clinical outcomes across all stages of the disease, as well as the lack of generic competition in China, Japan and Australia.
Deekshita Allavarapu, Analyst for GBI Research, expects the leading brands, Revlimid, Velcade and Thalomid, to continue to perform strongly in the APAC multiple myeloma treatment space, with minimal generic competition at present.
During the forecast period, these existing treatments for multiple myeloma will be supplemented by new drugs, many of which will be used in combination with the leading brands.
Other promising multiple myeloma pipeline drugs are Zolinza, filanesib and plitidepsin. However, no clinical trial is registered for these treatments in the APAC countries and they are only expected to launch towards the end of forecast period, according to GBI Research.